- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02080260
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
19 de abril de 2022 actualizado por: Wake Forest University Health Sciences
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
This study tests regorafenib as a single agent in the treatment of metastatic pancreatic cancer patients who have progressed after prior chemotherapy with gemcitabine.
The prognosis for these patients is particularly grim, no other standard treatment options exist, and novel approaches are desperately needed.
Descripción general del estudio
Descripción detallada
This is a single arm, single stage Phase II study designed to evaluate progression free survival (PFS) in patients with metastatic pancreatic cancer who have failed at least one prior line of therapy and treatment with gemcitabine.
This study is open at the Levine Cancer Institute (LCI).
A total of 32 patients will be enrolled over a two years.
Following informed consent and eligibility check, all patients will start oral regorafenib therapy (120 mg daily for 3 weeks on / 1 week off; 28 day cycle) with a built-in dose escalation to 160mg after the first cycle as tolerated, and will continue therapy until progression or patient withdrawal.
Patients will undergo radiological staging after the first two cycles of regorafenib therapy.
Patients with progressive disease will be removed from the study.
Patients who have at least stable disease will continue regorafenib therapy, at the Investigator's discretion, and will be radiologically restaged bimonthly.
Tipo de estudio
Intervencionista
Inscripción (Actual)
20
Fase
- Fase 2
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
North Carolina
-
Albemarle, North Carolina, Estados Unidos, 28001
- Levine Cancer Institute-Albemarle
-
Charlotte, North Carolina, Estados Unidos, 28204
- Levine Cancer Institute
-
Charlotte, North Carolina, Estados Unidos, 28211
- Levine Cancer Institute - Southpark
-
Charlotte, North Carolina, Estados Unidos, 28262
- Levine Cancer Institute - University
-
Charlotte, North Carolina, Estados Unidos, 28277
- Levine Cancer Institute - Ballantyne
-
Charlotte, North Carolina, Estados Unidos, 28203
- Levine Cancer Institute-South Tryon
-
Charlotte, North Carolina, Estados Unidos, 28210
- Levine Cancer Institute - Pineville
-
Charlotte, North Carolina, Estados Unidos, 28262
- Levine Cancer Institute - Mallard Creek
-
Concord, North Carolina, Estados Unidos, 28025
- Levine Cancer Institute - Concord
-
Monroe, North Carolina, Estados Unidos, 28112
- Levine Cancer Institute-Monroe
-
Shelby, North Carolina, Estados Unidos, 28150
- Levine Cancer Institute - Cleveland
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29406
- Low Country Hematology Oncology
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Adenocarcinoma of the exocrine pancreas with metastatic disease.
- The site of the primary tumor confirmed to have been within the pancreas.
- Progression on at least one prior line of chemotherapy for locally-advanced or metastatic pancreatic cancer.
- Progression while on treatment with a gemcitabine regimen for advanced pancreatic cancer, or within 12 months of treatment with gemcitabine as part of adjuvant therapy.
- Measurable disease on axial imaging.
- Age greater than or equal to 18 years.
- Life expectancy of at least 8 weeks.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2. Enrollment of patients with PS = 2 will be capped at 7 patients.
- Subjects must be able to understand and be willing to sign the written informed consent form.
- Acute toxic effects except alopecia of any prior treatment must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Grade 1 or less.
- Adequate bone marrow, renal, and liver function.
- Warfarin or heparin will be allowed provided that there is no prior evidence of underlying coagulation abnormality.
- Women of childbearing potential must have a negative pregnancy test performed within 7 days prior to the start of study drug. Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test.
- Patients (men and women) of childbearing potential must agree to use adequate contraception
- Patient must be able to swallow and retain oral medication.
Exclusion Criteria:
- Previous assignment to treatment during this study.
- Uncontrolled hypertension.
- Active clinically significant cardiac disease.
- Cerebrovascular arterial event within 6 months.
- Evidence or history of bleeding diathesis or coagulopathy.
- Any bleeding event greater than or equal to NCI CTCAE Grade 3 within 4 weeks.
- New venous thrombotic or embolic events, such as deep vein thrombosis or pulmonary embolism within 3 months.
- Previously untreated or concurrent cancer that is distinct in primary site or histology except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor. Patients surviving a cancer that was curatively treated and without evidence of disease for more than 3 years are allowed.
- Patients with pheochromocytoma.
- Known history of HIV infection or current chronic or active hepatitis B or C, requiring antiviral medication.
- Ongoing infection greater than or equal to Grade 2 NCI-CTCAE v4.0.
- Symptomatic metastatic brain or meningeal tumors.
- Presence of a non-healing wound, non-healing ulcer, or bone fracture.
- Renal failure requiring dialysis.
- Dehydration Grade greater than or equal to 1 NCI-CTCAE v4.0.
- Patients with seizure disorder requiring medication.
- Persistent proteinuria greater than or equal to Grade 3 NCI-CTCAE v4.0.
- Symptomatic interstitial lung disease.
- Pleural effusion or ascites that cause respiratory compromise.
- History of organ allograft except corneal transplant.
- Known or suspected allergy or hypersensitivity to the study drugs.
- Any severe, uncontrolled malabsorption condition.
- Women who are pregnant or breast-feeding.
- Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study.
- Concurrent anti-cancer therapy other than study treatment (regorafenib).
- Prior use of regorafenib.
- Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks.
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days.
- Prior radiation therapy or hepatic arterial therapy is permitted if more than 4 weeks have passed since completion and measurable disease outside of the treated area is present, or if progression since treatment has occurred.
- Use of St. John's Wort.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Single Arm
Oral Regorafenib
|
Single agent drug therapy with regorafenib
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Patients Progression Free and Surviving at 16 Weeks as a Percent of All Enrolled Subjects
Periodo de tiempo: 16 weeks after enrollment
|
16-week progression free survival was determined for each subject as a binary variable indicating whether or not the subject is alive and progression free at 16 weeks after treatment start, with progression defined radiographically using RECIST v1.1 or clinically based upon investigator assessment.
|
16 weeks after enrollment
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Progression Free Survival
Periodo de tiempo: From date of treatment start to date of progression or death, or censored as described above; assessed for approximately 3 years.
|
PFS is defined as duration of time from enrollment to the study to time of progression or death.
Disease progression (PD) can be objectively determined as per RECIST v1.1 (Response Evaluation Criteria in Solid Tumors, where PD is defined as a 20% increase in the sum of the longest diseased of target lesions, or a measurable increase in non-target lesion, or the appearance of new lesions) or progression can be subjective as determined by the investigator.
Evidence for subjective progressions must be documented in medical records.
For surviving subjects who do not have documented PD, PFS will be censored at last radiologic assessment.
For subjects who receive subsequent anti-cancer therapy prior to documented PD, PFS will be censored at last radiologic assessment prior to commencement of subsequent therapy.
Subjects who experience a PFS event following an interval equal to two or more scheduled CT assessments will be censored at date of last assessment prior to first missed assessment.
|
From date of treatment start to date of progression or death, or censored as described above; assessed for approximately 3 years.
|
Overall Survival
Periodo de tiempo: From date of treatment start to date of death, or censored as described above; assessed for approximately 3 years.
|
Overall survival is defined as the duration from enrollment date to the date of death from any cause.
Subjects who are alive or lost to follow-up at the time of the analysis will be censored at the last known date they were alive.
|
From date of treatment start to date of death, or censored as described above; assessed for approximately 3 years.
|
Overall Response
Periodo de tiempo: From enrollment to best response while on regorafenib; Subjects remained on treatment until disease progression or death or discontinuation from study or at least 28 days after last dose (subjects were on treatment for an average of 6 weeks)
|
Overall response will be determined as the best treatment response for each patient as a binary variable indicating whether or not the patient achieved a Complete Response (CR) or Partial Response (PR) as determined by RECIST v1.1 criteria.
Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1):Complete Response (CR) is the disappearance of all lesions (target and non target); Partial Response (PR) is at least 30% decrease in the sum of the diameters of target lesions from baseline and no new lesions or unequivocal progression in non target lesions from baseline; Stable Disease (SD) is neither sufficient shrinkage in target lesions to qualify for PR (less than 30% decrease) nor sufficient increase in target lesions (versus smallest sum of diameters) to qualify for PD (less than 20% increase), with no new lesions or unequivocal progression in non target lesions from baseline.
For the purposes of response determination, confirmatory scan for CR and PR is not required.
|
From enrollment to best response while on regorafenib; Subjects remained on treatment until disease progression or death or discontinuation from study or at least 28 days after last dose (subjects were on treatment for an average of 6 weeks)
|
Disease Control
Periodo de tiempo: From enrollment to best response while on regorafenib; Subjects remained on treatment until disease progression or death or discontinuation from study or at least 28 days after last dose (subjects were on treatment for an average of 6 weeks)
|
Disease control will be determined for each patient as a binary variable indicating whether or not the patient achieved a best overall best response of CR, PR, or stable disease as determined by RECIST v1.1 criteria.
Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v 1.1): Complete Response (CR) is the disappearance of all lesions (target and non target); Partial Response (PR) is at least 30% decrease in the sum of the diameters of target lesions from baseline and no new lesions or unequivocal progression in non target lesions from baseline; Stable Disease (SD) is neither sufficient shrinkage in target lesions to qualify for PR (less than 30% decrease) nor sufficient increase in target lesions (versus smallest sum of diameters) to qualify for PD (less than 20% increase), with no new lesions or unequivocal progression in non target lesions from baseline.
|
From enrollment to best response while on regorafenib; Subjects remained on treatment until disease progression or death or discontinuation from study or at least 28 days after last dose (subjects were on treatment for an average of 6 weeks)
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: John S Salmon, MD, Atrium Health Levine Cancer Institute
- Investigador principal: Edward Kim, MD, Atrium Health Levine Cancer Institute
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
6 de junio de 2014
Finalización primaria (Actual)
28 de junio de 2017
Finalización del estudio (Actual)
28 de junio de 2017
Fechas de registro del estudio
Enviado por primera vez
3 de marzo de 2014
Primero enviado que cumplió con los criterios de control de calidad
4 de marzo de 2014
Publicado por primera vez (Estimar)
6 de marzo de 2014
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
21 de abril de 2022
Última actualización enviada que cumplió con los criterios de control de calidad
19 de abril de 2022
Última verificación
1 de julio de 2019
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- LCI-GI-PAN-REG-001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cancer de pancreas
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Rabin Medical CenterReclutamiento
Ensayos clínicos sobre regorafenib
-
Zhongda HospitalSun Yat-sen University; Jiangsu Cancer Institute & Hospital; Zhejiang University; The Central Hospital of Lishui City y otros colaboradoresAún no reclutandoCarcinoma hepatocelular
-
Second Affiliated Hospital of Guangzhou Medical...Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Shenzhen... y otros colaboradoresActivo, no reclutandoCarcinoma hepatocelular no resecablePorcelana
-
Spanish Cooperative Group for the Treatment of...BayerTerminadoNeoplasias colorrectales | Enfermedad metásticaEspaña
-
Rennes University HospitalReclutamiento
-
Taipei Veterans General Hospital, TaiwanChang Gung Memorial Hospital; Koo Foundation Sun Yat-Sen Cancer CenterTerminadoCáncer colorrectal metastásicoTaiwán
-
Spanish Cooperative Group for the Treatment of...BayerTerminadoCáncer colorrectal metastásicoEspaña
-
BayerTerminadoNeoplasmaEstados Unidos
-
Tianjin Medical University Cancer Institute and...Aún no reclutandoCáncer colorrectal avanzado/metastásicoPorcelana
-
Institute of Mother and Child, Warsaw, PolandMaria Sklodowska-Curie National Research Institute of OncologyReclutamientoOsteosarcoma | Sarcoma óseo de EwingPolonia
-
Massachusetts General HospitalBayerTerminadoLeucemia mieloide agudaEstados Unidos